PDCD1 and melanoma: revealed that memory B‐cell‐derived gene profiles were correlated with higher response rates and longer PFS in melanoma and urothelial carcinoma patients treated with ICIs.[127] Improved OS in melanoma patients treated with PD‐1 inhibitors was also significantly correlated with plasmablast characterization.[32]